Kawasaki Disease (KWD)

Categories: Bone diseases, Cardiovascular diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Kawasaki Disease

MalaCards integrated aliases for Kawasaki Disease:

Name: Kawasaki Disease 57 11 19 42 58 73 53 41 2 14 63 75 33
Mucocutaneous Lymph Node Syndrome 57 11 19 42 58 73 43 16 71 33
Acute Febrile Mucocutaneous Lymph Node Syndrome 11 42 28 33
Kawasaki Syndrome 19 42 75 33
Kawasaki Disease, Susceptibility to 12 5 38
Infantile Polyarteritis 57 73 71
Kd 57 42 2
Acute Febrile Mcls 11
Kawasaki's Disease 11
Mlns 11
Kwd 73



Multigenic/multifactorial 58

Age Of Onset:

Adolescent,Adult,Childhood,Infancy 58


Orphanet: 58  
Rare circulatory system diseases
Rare systemic and rhumatological diseases

Summaries for Kawasaki Disease

MedlinePlus: 41 What is Kawasaki disease? Kawasaki disease is a rare illness that usually affects small children. Other names for it are Kawasaki syndrome and mucocutaneous lymph node syndrome. It is a type of vasculitis, which is inflammation of the blood vessels. Kawasaki disease is serious, but most children can fully recover if they are treated right away. What causes Kawasaki disease? Kawasaki disease happens when the immune system injures the blood vessels by mistake. Researchers do not fully know why this happens. But when it does, the blood vessels become inflamed and can narrow or close off. Genetics may play a role in Kawasaki disease. There may also be environmental factors, such as infections. It does not seem to be contagious. This means that it cannot be passed from one child to another. Who is at risk for Kawasaki disease? Kawasaki disease usually affects children under the age of 5. But older children and adults can sometimes get it. It is more common in boys than girls. It can affect children of any race, but those with Asian or Pacific Islander descent are more likely to get it. What are the symptoms of Kawasaki disease? The symptoms of Kawasaki disease may include: High fever lasting at least five days A rash, often on the back, chest, and groin Swollen hands and feet Redness of the lips, lining of the mouth, tongue, palms of the hand, and soles of the feet Pink eye Swollen lymph nodes What other problems can Kawasaki disease cause? Sometimes Kawasaki disease can affect the walls of the coronary arteries. These arteries bring supply blood and oxygen to your heart. This can lead to: An aneurysm (bulging and thinning of the walls of the arteries). This can raise the risk of blood clotss in the arteries. If the blood clots are not treated, they could lead to a heart attack or internal bleeding. Inflammation in the heart Heart valve problems Kawasaki disease can also affect other parts of the body, including the brain and nervous system, the immune system, and the digestive system. How is Kawasaki disease diagnosed? There is no specific test for Kawasaki disease. To make a diagnosis, your child's health care provider may use many tools: A physical exam, which includes looking at the signs and symptoms Blood and urine tests to rule out other diseases and check for signs of inflammation Tests to check for damage to the heart, such as an echocardiogram and electrocardiogram (EKG) What are the treatments for Kawasaki disease? Kawasaki disease is usually treated in the hospital with an intravenous (IV) dose of immunoglobulin (IVIG). Aspirin may also be part of the treatment. But do not give your child aspirin unless the health care provider tells you to. Aspirin can cause Reye syndrome in children. This is a rare, serious illness that can affect the brain and liver. Usually treatment works. But if it is not working well enough, the provider may also give your child other medicines to fight the inflammation. If the disease affects your child's heart, he or she might need additional medicines, surgery, or other medical procedures.

MalaCards based summary: Kawasaki Disease, also known as mucocutaneous lymph node syndrome, is related to exanthem and conjunctivitis, and has symptoms including fever, congestion of ocular conjunctivae and reddening of lips. An important gene associated with Kawasaki Disease is THRIL (TNF And HNRNPL Related Immunoregulatory Long Non-Coding RNA), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Immunologic Factors and Immunoglobulins, Intravenous have been mentioned in the context of this disorder. Affiliated tissues include body, lymph node and heart, and related phenotypes are proteinuria and cheilitis

OMIM®: 57 Kawasaki disease is an acute, self-limited vasculitis of infants and children characterized by prolonged fever unresponsive to antibiotics, polymorphous skin rash, erythema of the oral mucosa, lips, and tongue, erythema of the palms and soles, bilateral conjunctival injection, and cervical lymphadenopathy (Kawasaki, 1967). Coronary artery aneurysms develop in 15 to 25% of those left untreated (11,12:Kato et al., 1975, 1996), making Kawasaki disease the leading cause of acquired heart disease among children in developed countries. Treatment with intravenous immunoglobulin (IVIg) abrogates the inflammation in approximately 80% of affected individuals and reduces the aneurysm rate to less than 5%. Cardiac sequelae of the aneurysms include ischemic heart disease, myocardial infarction, and sudden death. Epidemiologic features such as seasonality and clustering of cases suggested an infectious trigger, although no pathogen had been isolated. Several lines of evidence suggested the importance of genetic factors in disease susceptibility and outcome. First, the incidence of Kawasaki disease is 10 to 20 times higher in Japan than in Western countries (Cook et al., 1989). Second, the risk of Kawasaki disease in sibs of affected children is 10 times higher than in the general population, and the incidence of Kawasaki disease in children born to parents with a history of Kawasaki disease is twice as high as that in the general population (Fujita et al., 1989; Uehara et al., 2003). Hata and Onouchi (2009) reviewed current knowledge on Kawasaki disease, including epidemiology, genomewide linkage analysis, and molecular genetics. (611775) (Updated 08-Dec-2022)

MedlinePlus Genetics: 42 Kawasaki disease is a sudden and time-limited (acute) illness that affects infants and young children. Affected children develop a prolonged fever lasting several days, a skin rash, and swollen lymph nodes in the neck (cervical lymphadenopathy). They also develop redness in the whites of the eyes (conjunctivitis) and redness (erythema) of the lips, lining of the mouth (oral mucosa), tongue, palms of the hands, and soles of the feet.Without treatment, 15 to 25 percent of individuals with Kawasaki disease develop bulging and thinning of the walls of the arteries that supply blood to the heart muscle (coronary artery aneurysms) or other damage to the coronary arteries, which can be life-threatening.

GARD: 19 Kawasaki disease is a disease that involves inflammation of the blood vessels. It is typically diagnosed in young children, but older children and adults can also develop this condition. Kawasaki disease begins with a fever that lasts at least five days. Other classic symptoms may include red eyes, lips, and mouth; rash; swollen and red hands and feet; and swollen lymph nodes. Sometimes the disease affects the coronary arteries which carry oxygen-rich blood to the heart, which can lead to serious heart problems. Kawasaki disease occurs most often in people of Asian and Pacific Island descent. The cause of Kawasaki disease is unknown. An infection along with genetic factors may be involved.

PubMed Health : 63 Kawasaki disease: Kawasaki (KAH-wah-SAH-ke) disease is a rare childhood disease. It's a form of a condition called vasculitis (vas-kyu-LI-tis). This condition involves inflammation of the blood vessels. In Kawasaki disease, the walls of the blood vessels throughout the body become inflamed. The disease can affect any type of blood vessel in the body, including the arteries, veins, and capillaries. Sometimes Kawasaki disease affects the coronary arteries, which carry oxygen-rich blood to the heart. As a result, some children who have Kawasaki disease may develop serious heart problems.

Disease Ontology: 11 A lymphadenitis characterized by swelling of cervical lymph nodes in infants and young children and inflammation of medium-sized blood vessels located in body, has symptom fever, has symptom congestion of ocular conjunctivae, has symptom reddening of lips, has symptom reddening of oral cavity, has symptom protuberance of tongue papillae and has symptom edema of extremities.

CDC: 2 Kawasaki disease (KD), also known as Kawasaki syndrome, is an acute febrile illness of unknown etiology that primarily affects children younger than 5 years of age. The disease was first described in Japan by Tomisaku Kawasaki in 1967, and the first cases outside of Japan were reported in Hawaii in 1976.

Orphanet: 58 A rare inflammatory disease characterized by an acute febrile, systemic, self-limiting, medium-vessel vasculitis primarily affecting children. It often causes acute coronary arteritis which is associated with coronary arterial aneurysms (CAA) that may be life threatening when untreated.

UniProtKB/Swiss-Prot: 73 An acute, self-limited vasculitis of infants and children characterized by prolonged fever unresponsive to antibiotics, polymorphous skin rash, erythema of the oral mucosa, lips, and tongue, erythema of the palms and soles, bilateral conjunctival injection, and cervical lymphadenopathy.

Wikipedia: 75 Kawasaki disease is a syndrome of unknown cause that results in a fever and mainly affects children... more...

Related Diseases for Kawasaki Disease

Diseases related to Kawasaki Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 918)
# Related Disease Score Top Affiliating Genes
1 exanthem 32.1 TNF GPT CRP
2 conjunctivitis 31.9 TNF MMP9 CCL2
3 vasculitis 31.9 TNF SELL SELE MBL2 HSPD1 ELANE
4 myocarditis 31.8 TNF NPPB MMP9 CCL2
5 lymphadenitis 31.6 TNF ITPKC CRP
6 pyuria 31.6 ITPKC GPT CRP
7 mitral valve insufficiency 31.5 NPPB GPT CRP
8 pericardial effusion 31.4 TNF NPPB GPT CRP
9 coronary aneurysm 31.4 TNF NPPB MMP9 MMP3 ITPKC GPT
10 rheumatic fever 31.4 TNF NPPB MBL2 FCGR2A
11 coronary stenosis 31.4 SELL NPPB CRP
12 purpura 31.4 TNF FCGR2A CRP
13 severe acute respiratory syndrome 31.4 TNF MBL2 GPT CRP CCL2
14 covid-19 31.3 TNF NPPB FCGR2A CRP CCL2
15 pharyngitis 31.3 TNF GPT CRP
16 viral infectious disease 31.2 TNF MYD88 MBL2 GPT CCL2
17 pericarditis 31.2 TNF NPPB CRP
18 urinary tract infection 31.2 TNF GPT CRP
19 scarlet fever 31.2 TNF ITPKC CRP
20 hemophagocytic lymphohistiocytosis 31.1 TNF GPT CRP CCL2
21 cervical adenitis 31.1 TNF ITPKC HSPD1 CRP
22 cellulitis 31.1 TNF GPT CRP
23 hydrops of gallbladder 31.1 NPPB ITPKC GPT FCGR2A CRP
24 angina pectoris 31.1 TNF NPPB CRP
25 cardiac tamponade 31.1 NPPB GPT CRP
26 vascular disease 31.1 TNF TIMP1 SELE MMP9 MMP3 HSPD1
27 acute myocarditis 31.0 TNF NPPB CRP
28 endocarditis 31.0 TNF HSPD1 FCGR2A CRP
29 chickenpox 31.0 TNF GPT CRP
30 deficiency anemia 31.0 TNF TIMP1 GPT FCGR2A CRP
31 tricuspid valve insufficiency 31.0 NPPB GPT CRP
32 polyarteritis nodosa 31.0 TNF SELL SELE GPT CRP
33 juvenile rheumatoid arthritis 31.0 TNF HSPD1 CRP
34 cholangitis 30.9 TNF GPT CRP
35 bacterial conjunctivitis 30.9 TNF NPPB ITPKC GPT CRP
36 familial mediterranean fever 30.8 TNF S100A12 CRP
37 appendicitis 30.8 TNF MMP9 CRP CCL2
38 autoimmune vasculitis 30.8 TNF ITPKC FCGR2A ELANE CRP
39 intestinal obstruction 30.8 TNF GPT CRP
40 rheumatic heart disease 30.8 TNF NPPB MBL2
41 ileus 30.8 TNF CRP CCL2
42 atherosclerosis susceptibility 30.8 TNF SELE MMP9 HSPD1 CRP CCL2
43 severe cutaneous adverse reaction 30.8 TNF GPT CRP
44 autoimmune disease 30.8 TNF MMP9 MBL2 HSPD1 FCGR2A CRP
45 severe covid-19 30.7 TNF GPT CRP CCL2
46 meningitis 30.7 TNF TIMP1 MMP9 MBL2 FCGR2A CRP
47 aortic aneurysm 30.7 TNF TIMP1 MMP9 MMP3 ELANE CRP
48 acalculous cholecystitis 30.7 GPT CRP
49 acute myocardial infarction 30.7 TNF SELE NPPB MMP9 CRP ADM
50 glucosephosphate dehydrogenase deficiency 30.7 TNF GPT CRP

Graphical network of the top 20 diseases related to Kawasaki Disease:

Diseases related to Kawasaki Disease

Symptoms & Phenotypes for Kawasaki Disease

Human phenotypes related to Kawasaki Disease:

58 30 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 proteinuria 58 30 Hallmark (90%) Very frequent (99-80%)
2 cheilitis 58 30 Hallmark (90%) Very frequent (99-80%)
3 recurrent pharyngitis 58 30 Hallmark (90%) Very frequent (99-80%)
4 conjunctivitis 58 30 Hallmark (90%) Very frequent (99-80%)
5 skin rash 58 30 Hallmark (90%) Very frequent (99-80%)
6 vasculitis 58 30 Hallmark (90%) Very frequent (99-80%)
7 cervical lymphadenopathy 58 30 Hallmark (90%) Very frequent (99-80%)
8 palmoplantar erythema 58 30 Hallmark (90%) Very frequent (99-80%)
9 arthritis 58 30 Frequent (33%) Frequent (79-30%)
10 fatigue 58 30 Frequent (33%) Frequent (79-30%)
11 fever 58 30 Frequent (33%) Frequent (79-30%)
12 abnormal heart valve morphology 58 30 Frequent (33%) Frequent (79-30%)
13 abdominal pain 58 30 Frequent (33%) Frequent (79-30%)
14 pericarditis 58 30 Frequent (33%) Frequent (79-30%)
15 glossitis 58 30 Frequent (33%) Frequent (79-30%)
16 diarrhea 58 30 Frequent (33%) Frequent (79-30%)
17 edema 58 30 Frequent (33%) Frequent (79-30%)
18 leukocytosis 58 30 Frequent (33%) Frequent (79-30%)
19 abnormality of nail color 58 30 Frequent (33%) Frequent (79-30%)
20 nausea and vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
21 ptosis 58 30 Occasional (7.5%) Occasional (29-5%)
22 cranial nerve paralysis 58 30 Occasional (7.5%) Occasional (29-5%)
23 congestive heart failure 58 30 Occasional (7.5%) Occasional (29-5%)
24 hepatitis 58 30 Occasional (7.5%) Occasional (29-5%)
25 irritability 58 30 Occasional (7.5%) Occasional (29-5%)
26 jaundice 58 30 Occasional (7.5%) Occasional (29-5%)
27 arthralgia 58 30 Occasional (7.5%) Occasional (29-5%)
28 arrhythmia 58 30 Occasional (7.5%) Occasional (29-5%)
29 migraine 58 30 Occasional (7.5%) Occasional (29-5%)
30 myocarditis 58 30 Occasional (7.5%) Occasional (29-5%)
31 meningitis 58 30 Occasional (7.5%) Occasional (29-5%)
32 cholecystitis 58 30 Occasional (7.5%) Occasional (29-5%)
33 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis 58 30 Occasional (7.5%) Occasional (29-5%)
34 sterile pyuria 58 30 Occasional (7.5%) Occasional (29-5%)
35 ascending tubular aorta aneurysm 30 Occasional (7.5%) HP:0004970
36 abnormal pulmonary interstitial morphology 30 Occasional (7.5%) HP:0006530
37 dilatation of the ascending aorta 58 Occasional (29-5%)
38 interstitial pulmonary abnormality 58 Occasional (29-5%)

Clinical features from OMIM®:

611775 (Updated 08-Dec-2022)


  • fever
  • congestion of ocular conjunctivae
  • reddening of lips
  • reddening of
  • protuberance of tongue papillae
  • edema of extremities

UMLS symptoms related to Kawasaki Disease:

angina pectoris; chest pain; pruritus; edema; exanthema

GenomeRNAi Phenotypes related to Kawasaki Disease according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCL2 FCGR2A HSPD1 MYD88 S100A12 SELE

MGI Mouse Phenotypes related to Kawasaki Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.13 ADM BLK CCL2 CRP ELANE FCGR2A
2 cardiovascular system MP:0005385 10.1 ADM CCL2 CRP FCGR2A HSPD1 MMP9
3 neoplasm MP:0002006 9.91 CCL2 ELANE MMP9 MYD88 SELL TIMP1
4 hematopoietic system MP:0005397 9.83 ADM BLK CCL2 ELANE FCGR2A HSPD1
5 respiratory system MP:0005388 9.81 ADM FCGR2A HSPD1 MMP9 MYD88 SELE
6 integument MP:0010771 9.28 ADM CCL2 ELANE HSPD1 MMP9 MYD88

Drugs & Therapeutics for Kawasaki Disease

PubMed Health treatment related to Kawasaki Disease: 63

Medicines are the main treatment for Kawasaki disease . Rarely, children whose coronary (heart ) arteries are affected may need medical procedures or surgery . The goals of treatment include: Reducing fever and inflammation to improve symptoms Preventing the disease from affecting the coronary arteries

Drugs for Kawasaki Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4
2 Immunoglobulins, Intravenous Phase 4
3 Immunoglobulins Phase 4
4 Antibodies Phase 4
5 Immunoglobulin G Phase 4
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
Prednisolone Approved, Vet_approved Phase 3 50-24-8 4894 5755
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5 1875
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 4159 6741
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7 4897
14 Radiopharmaceuticals Phase 3
15 Technetium Tc 99m Sestamibi Phase 3
16 Pharmaceutical Solutions Phase 3
17 Antineoplastic Agents, Hormonal Phase 3
18 Hormones Phase 3
19 Hormone Antagonists Phase 3
20 glucocorticoids Phase 3
Methylprednisolone Acetate Phase 3 584547
22 Interleukin 1 Receptor Antagonist Protein Phase 3
D-Alanine Experimental, Nutraceutical Phase 3 302-72-7, 338-69-2, 56-41-7 101757026 602 71080 5950
Etanercept Approved, Investigational Phase 2 185243-69-0
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
Acetylsalicylic acid Approved, Vet_approved Phase 2 50-78-2 2244
Atorvastatin Approved Phase 1, Phase 2 134523-00-5 60823
Defibrotide Approved, Investigational Phase 2 83712-60-1
29 Immunosuppressive Agents Phase 2
30 Antiprotozoal Agents Phase 2
31 Antiparasitic Agents Phase 2
32 Antimalarials Phase 2
33 Neuroprotective Agents Phase 1
34 Antiemetics Phase 1
35 Protective Agents Phase 1
Adenosine Approved, Investigational 58-61-7 60961
Dobutamine Approved 34368-04-2 36811
Budesonide Approved 51333-22-3 5281004 40000 63006
Dextroamphetamine Approved, Illicit, Investigational 51-64-9, 300-62-9 5826 3007
Amiodarone Approved, Investigational 1951-25-3 2157
Aminocaproic acid Approved, Investigational 60-32-2 564
Voriconazole Approved 137234-62-9 71616
Lopinavir Approved 192725-17-0 92727
Ritonavir Approved, Investigational 155213-67-5 392622
Risperidone Approved, Investigational 106266-06-2 5073
Ceftazidime Approved 78439-06-2, 72558-82-8 5481173
Dexmedetomidine Approved, Experimental, Vet_approved 86347-14-0, 113775-47-6 68602 5311068
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3 3680
Labetalol Approved 36894-69-6 3869
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 3003 5743

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Multicenter, Single-arm, Phase IV Study to Evaluate the Efficacy, Safety of Combined Therapy of Aspirin and IVIG-SN 10% in Pediatric Patients With Kawasaki Disease Completed NCT04003844 Phase 4 Immunoglobulin G;Acetylsalicylic acid
2 Multicenter, Single-arm, Phase IV Study to Evaluate the Efficacy, Safety of Combined Therapy of Aspirin and High Dose "IVIG-SN" in Pediatric Patients With Kawasaki Disease Completed NCT01524939 Phase 4 immunoglobulin G
3 A Randomized Open-label Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Unknown status NCT03200561 Phase 3 Prednisolone
4 Infliximab (Remicade®) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease Completed NCT00760435 Phase 3 Infliximab;Placebo
5 Infliximab for Kawasaki Disease Patients Resistant to Intravenous Immunoglobulin : a Multicentre, Prospective, Randomised Trial Completed NCT02298062 Phase 3 Infliximab;IVIG
6 KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Completed NCT03065244 Phase 3 IVIG;Infliximab
7 Different Doses of IVIG for Kawasaki Disease: a Multicentre, Prospective, Randomised Trial Completed NCT02439996 Phase 3 IVIG (1g/kg,once);IVIG (1g/kg,twice);IVIG (2g/kg.once)
8 A Phase III, Open-Label, Non-Randomized, International, Multicenter Trial to Evaluate the Efficacy and Safety of CARDIOLITE® Myocardial Perfusion Imaging in Pediatric Subjects With Kawasaki Disease Completed NCT00162032 Phase 3 Sestamibi
9 Trial of Pulse Steroid Therapy in Kawasaki Disease (A Trial Conducted by the Pediatric Heart Network) Completed NCT00132080 Phase 3 Steroids
10 To Evaluate the Efficacy and Safety of TA-650 in Comparison With a Control Drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in Patients With Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin (IVIG). Completed NCT01596335 Phase 3 TA-650;Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
11 A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders Completed NCT00157079 Phase 3
12 Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease: A Multicentre Randomised Controlled Trial Recruiting NCT04078568 Phase 3 IVIG;Aspirin;Prednisolone
13 A Randomized Phase III Multicenter Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment Not yet recruiting NCT04656184 Phase 3 ANAKINRA;Intravenous immunoglobulin
14 Efficacy of Primary Treatment With Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease: a Multicenter, Open-label, Blinded-end Randomized Controlled Study. Withdrawn NCT04535518 Phase 3 IVIG;Aspirin;Infliximab
15 A Randomized, Double Blind, Placebo Controlled Study of the Effects of Etanercept in Children Presenting With Kawasaki Disease Unknown status NCT00841789 Phase 2 Etanercept;Placebo
16 An Open Label, Non-comparative Phase II Trial to Evaluate the Effects of Atorvastatin on the Persistent Coronary Arterial Aneurysm in Children With Kawasaki Disease: Safety and Efficacy Unknown status NCT02114099 Phase 2 Atorvastatin
17 Phase 2 Study to Assess the Efficacy and Safety of Doxycycline in Preventing Coronary Artery Aneurysm Formation and Progression Unknown status NCT01917721 Phase 2 Doxycycline;Placebo
18 A Phase IIa Multicenter Trial to Assess the Efficacy, and Safety of Anakinra in Patients With Intravenous Immunoglobulin-resistant Kawasaki Disease Completed NCT02390596 Phase 2 Anakinra
19 Phase I/IIa Study of Pharmacokinetics and Safety of Atorvastatin in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease Completed NCT01431105 Phase 1, Phase 2 Atorvastatin
20 A Phase I-II, Open-Label, Multicenter Trial to Determine the Dosimetry and Safety of Technetium Tc99m Sestamibi in Pediatric Subjects Completed NCT00162045 Phase 1, Phase 2 Technetium Tc99m Sestamibi
21 Prevention of Coronary Aneurysms in Kawasaki Syndrome Completed NCT00000520 Phase 2 immunoglobulins, intravenous;aspirin
22 A Pilot Study to Determine the Safety of Defibrotide in Children With High Risk Kawasaki Disease Recruiting NCT04777422 Phase 2 Defibrotide
23 Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Active, not recruiting NCT02179853 Phase 1, Phase 2 Anakinra
24 Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Withdrawn NCT02980263 Phase 2 Canakinumab
25 Cardiovascular Risk Markers Before and After Therapy With Statins in Patients With History of Kawasaki Disease Withdrawn NCT00305201 Phase 2 pravastatin
26 Infliximab (Remicade) for Patients With Acute Kawasaki Disease Who Fail to Become Afebrile After Intravenous Gamma Globulin Therapy Completed NCT00271570 Phase 1 Infliximab (Remicade)
27 Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease Recruiting NCT04509219 Phase 1 Methylprednisolone Injection
28 Safety and Vascular Remodelling After Bioresorbable Vascular Scaffold Implantation for Stenotic or Occluded Lesions in Children and Young Adults With Kawasaki Disease Unknown status NCT02771288
29 Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan Unknown status NCT02951234
30 Etiology Study of Kawasaki Disease--A Prospective Household and Case Control Study Unknown status NCT00154596
31 Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease Unknown status NCT02359643 Aspirin
32 Measurement of Antibodies in Adults With a History of Kawasaki Disease Unknown status NCT02853266
33 Acute Abdomen in Kawasaki Disease: Case Reports Completed NCT03902262
34 Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017 Completed NCT03880929
35 Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Completed NCT02317913
36 Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease Completed NCT01440075
37 Quantification of Ventricular Mechanics/Myocardial Blood Flow Reserve in Adolescents and Adults Ages 12-50 With Congenital or Acquired Heart Disease Using Bicycle Stress With Real Time Myocardial Contrast Echo and Dobutamine Stress MRI Completed NCT00861848
38 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
39 Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease Recruiting NCT04747847 Early Phase 1 Atorvastatin and anakinra
40 Cardiovascular Status of Children 5 Years After Kawasaki Disease Recruiting NCT03750123
41 Clinical Precise Diagnosis and Treatment of Personalized Z-score Evaluation Combined With Genomic Analysis in the Repair of Coronary Artery Injury in Kawasaki Disease Recruiting NCT05347901
42 Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease Recruiting NCT04538495
43 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Recruiting NCT04278404 The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
44 Coordination of Rare Diseases at Sanford Recruiting NCT01793168
45 Genetic Determinants of Kawasaki Disease for Susceptibility and Outcome Active, not recruiting NCT03861130
46 Application of Statins in Long-term Treatments of Kawasaki Disease Complicated With Severe Coronary Artery Abnormalities in Children Active, not recruiting NCT03915795
47 A Cohort Study to Evaluate a Blood Test for Early-screening of Kawasaki Disease Not yet recruiting NCT05091229
48 Role of Calcium Binding Protein S100A12 in Diagnosis and Prognosis of Kawasaki Disease Not yet recruiting NCT05434611

Search NIH Clinical Center for Kawasaki Disease

Cochrane evidence based reviews: mucocutaneous lymph node syndrome

Genetic Tests for Kawasaki Disease

Genetic tests related to Kawasaki Disease:

# Genetic test Affiliating Genes
1 Acute Febrile Mucocutaneous Lymph Node Syndrome 28

Anatomical Context for Kawasaki Disease

Organs/tissues related to Kawasaki Disease:

FMA: Body
MalaCards : Lymph Node, Heart, Tongue, Skin, Brain, Liver, Bone

Publications for Kawasaki Disease

Articles related to Kawasaki Disease:

(show top 50) (show all 9380)
# Title Authors PMID Year
ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. 62 57 5
18084290 2008
GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease. 62 57
27595596 2016
A genome-wide association study identifies three new risk loci for Kawasaki disease. 62 57
22446962 2012
Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. 62 57
22446961 2012
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. 62 57
22081228 2011
ITPKC gene SNP rs28493229 and Kawasaki disease in Taiwanese children. 62 57
20045869 2010
Susceptibility genes for Kawasaki disease: toward implementation of personalized medicine. 62 57
19158812 2009
A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. 62 57
17160344 2007
Familial occurrence of Kawasaki syndrome in North America. 62 57
16143748 2005
Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. 62 57
15843588 2005
CD40 ligand gene and Kawasaki disease. 62 57
15367912 2004
Kawasaki syndrome. 62 57
15302199 2004
Kawasaki disease in parents and children. 62 57
12856980 2003
Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. 62 57
12563087 2003
Two-generation Kawasaki disease: mother and daughter. 62 57
11713463 2001
Kawasaki disease in a father and daughter. 62 57
10447146 1999
Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. 62 57
8822996 1996
Results from an international survey of Kawasaki disease in 1979-82. 62 57
2605549 1989
Kawasaki disease in families. 62 57
2780128 1989
An epidemic of Kawasaki syndrome in Hawaii. 62 57
7062202 1982
Kawasaki syndrome: description of two outbreaks in the United States. 62 57
7231502 1981
Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. 62 57
236368 1975
A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. 62 57
4153258 1974
Similarities and differences between MIS-C and KD: a systematic review and meta-analysis. 62 41
36471327 2022
Multisystem inflammatory syndrome in children in Singapore. 62 41
36453214 2022
Inflammatory responses in SARS-CoV-2 associated Multisystem Inflammatory Syndrome and Kawasaki Disease in children: An observational study. 62 41
36449533 2022
[Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. 57
6062087 1967
[Levels of serum brain natriuretic peptide and the correlation to heart function in children with Kawasaki disease]. 53 62
20350422 2010
Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease. 53 62
19945447 2010
Association of mannose-binding lectin gene polymorphisms with Kawasaki disease in the Japanese. 53 62
20374367 2009
[Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease]. 53 62
20113606 2009
[Effect of small interfering RNA on matrix metalloproteinase-9 expression in vascular endothelial cells stimulated by serum from children with Kawasaki disease]. 53 62
20128385 2009
Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. 53 62
19604270 2009
Amino-terminal pro-B-type natriuretic peptide in refractory Kawasaki disease. 53 62
19365663 2009
Brain natriuretic peptide levels in Kawasaki disease: a case report. 53 62
19500284 2009
Association of the matrix metalloproteinase-3 (-439C/G) promoter polymorphism with Kawasaki disease in Korean children. 53 62
18810583 2008
Inflammatory gene polymorphisms and susceptibility to kawasaki disease and its arterial sequelae. 53 62
18710885 2008
Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. 53 62
18311803 2008
[Biochemical and immunological laboratory findings in Kawasaki disease]. 53 62
18260330 2008
[Expression of monocyte chemotactic protein-1 in peripheral blood mononuclear cells of children with Kawasaki disease and its relation to coronary artery impairment]. 53 62
19099689 2008
[Reducing plasma homocysteic acid lowers serum C-reactive protein level in children with Kawasaki disease]. 53 62
18024309 2007
Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease. 53 62
17932598 2007
Levels of intra- and extracellular heat shock protein 60 in Kawasaki disease patients treated with intravenous immunoglobulin. 53 62
17602873 2007
Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation? 53 62
17949555 2007
Increased CD11b expression on polymorphonuclear leucocytes and cytokine profiles in patients with Kawasaki disease. 53 62
17286760 2007
Abnormal tissue doppler images are associated with elevated plasma brain natriuretic peptide and increased oxidative stress in acute Kawasaki disease. 53 62
17322635 2007
Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. 53 62
16896641 2007
[Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice]. 53 62
17254452 2006
Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis. 53 62
17140160 2006
The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. 53 62
16990356 2006

Variations for Kawasaki Disease

ClinVar genetic disease variations for Kawasaki Disease:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ITPKC NM_025194.3(ITPKC):c.1155+9G>C SNV Risk Factor
4277 rs28493229 GRCh37: 19:41224204-41224204
GRCh38: 19:40718299-40718299

Expression for Kawasaki Disease

Search GEO for disease gene expression data for Kawasaki Disease.

Pathways for Kawasaki Disease

Pathways related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.21 TNF TIMP1 S100A12 MYD88 MMP9 MMP3
Show member pathways
Show member pathways
12.16 CCL2 MMP3 MMP9 TNF
5 11.87 TNF MMP9 FCGR2A CCL2
6 11.78 TIMP1 MMP3 CCL2
7 11.75 TNF TIMP1 MMP9 MMP3 CCL2
8 11.73 CCL2 MMP3 MMP9 TIMP1
Show member pathways
10 11.64 TNF SELL CRP
11 11.62 TIMP1 MMP9 CCL2
12 11.57 TNF MYD88 ELANE
13 11.55 TIMP1 MMP9 MMP3
Show member pathways
15 11.5 TNF TIMP1 MMP9 CCL2
16 11.46 TNF SELE CCL2
17 11.41 TNF TIMP1 CCL2
18 11.36 TNF MYD88 CCL2
19 11.3 MMP9 MMP3 ELANE
20 11.23 TNF TIMP1 MYD88 MMP9 CCL2
21 11.18 TNF MMP3 CCL2
22 11.12 TNF MMP9 CCL2
23 10.84 TIMP1 MYD88 MMP9 CCL2

GO Terms for Kawasaki Disease

Cellular components related to Kawasaki Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10 TNF TIMP1 S100A12 NPPB MMP9 MMP3
2 extracellular space GO:0005615 9.75 ADM CCL2 CRP ELANE GPT HSPD1

Biological processes related to Kawasaki Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 10.06 TNF S100A12 MYD88 MBL2 ELANE
2 defense response to Gram-positive bacterium GO:0050830 10.03 TNF MYD88 MBL2 CRP
3 inflammatory response GO:0006954 9.97 TNF SELE S100A12 MYD88 CRP CCL2
4 extracellular matrix disassembly GO:0022617 9.95 MMP9 MMP3 ELANE
5 lipopolysaccharide-mediated signaling pathway GO:0031663 9.93 TNF MYD88 CCL2
6 response to lipopolysaccharide GO:0032496 9.92 ADM ELANE MYD88 SELE TNF
7 leukocyte tethering or rolling GO:0050901 9.85 TNF SELL SELE
8 leukocyte migration involved in inflammatory response GO:0002523 9.73 TNF SELE ELANE
9 cellular response to UV-A GO:0071492 9.43 TIMP1 MMP9 MMP3
10 leukocyte migration GO:0050900 9.1 TNF SELL SELE MMP9 ELANE

Molecular functions related to Kawasaki Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.56 TNF TIMP1 SELL ELANE
2 signaling receptor binding GO:0005102 9.4 TNF NPPB MYD88 MBL2 CCL2 BLK

Sources for Kawasaki Disease

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....